Table 1 Baseline patient characteristics

Patient age median (range)

71(49–83)

69(49–81)

72(63–81)

71(52–83)

Follow-up period/months median (range)

108(7–157)

120(8–150)

111(7–157)

105(9–149)

T stage > 2a

21%

5%

36%

25%

Gleason score >6

13%

3%

18%

17%

Primary PSA/ng/ml median (range)

9(1–300)

7(1–15)

13(1–300)

10(1–150)

Low risk patients^a

43%

65%

27%

35%

Intermediate risk patients^b

29%

35%

24%

26%

High risk patients^c

29%

0%

49%

39%

NHT

44%

35%

56%

47%

NHT/months median (range)

4(1–28)

3(1–8)

5(1–28)

5(1–18)